Eculizumab

Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC) . Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies[1][2].

Product Specifications

CAS Number

[219685-50-4]

Product Name Alternative

Anti-Human C5, Humanized Antibody; h5G1.1

UNSPSC

12352203

Target

Complement System

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/eculizumab.html

Purity

99.88

Solubility

H2O

Smiles

[Eculizumab]

Molecular Weight

(145.74 kDa)

References & Citations

[1]Eline A Dubois, et al. Eculizumab. Br J Clin Pharmacol. 2009 Sep;68 (3) :318-9.|[2]Halstead SK, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain. 2008 May;131 (Pt 5) :1197-208.